You are here: Industry Insights > DelMar

News List

DelMar Updates Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors americanpharmaceuticalreview
May 07, 2020
DelMar Pharmaceuticals has enrolled 22 patients in the adjuvant arm of the Company's ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide -- or TMZ -- maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) ...
DelMar Pharmaceuticals Relocates Headquarters to San Diego americanpharmaceuticalreview
September 09, 2019
DelMar Pharmaceuticals announced the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California.
DelMar Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 americanpharmaceuticalreview
August 01, 2019
DelMar Pharmaceuticals has achieved two-thirds enrollment in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed MGMT-unmethylated GBM.
DelMar Announces Accelerated Patient Enrollment of Trial in MGMT-unmethylated Recurrent GBM americanpharmaceuticalreview
June 27, 2018
DelMar updated patient enrollment data for its Phase 2 open-label clinical trial of VAL-083 in bevacizumab (Avastin)-naïve recurrent glioblastoma multiforme (rGBM) patients with MGMT-unmethylated status.
DelMar Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 americanpharmaceuticacreview
September 19, 2017
Twenty-four patients will be enrolled under the first phase of the VAL-083 REPROVe Trial with top line results expected within 18-24 months from trial initiation of patient treatment.
DelMar Collaborates with PRA Health Sciences contractpharma
May 12, 2017
CRO will conduct for phase 3 trial of VAL-083 in recurrent glioblastoma multiforme